Dr. Jaume Pons served as the CEO of ALX Oncology Holdings Inc. from December 22, 2020, until September 6, 2023, when he transitioned to the role of Chief Scientific Officer and President. Under his leadership, the company focused on developing...
Dr. Jaume Pons served as the CEO of ALX Oncology Holdings Inc. from December 22, 2020, until September 6, 2023, when he transitioned to the role of Chief Scientific Officer and President. Under his leadership, the company focused on developing innovative cancer therapies, demonstrating a strong commitment to pushing boundaries in biotechnology. In 2023, Dr. Pons had a total compensation of $1 million, with a salary of $649,740 and a bonus linked to corporate performance. He also managed significant stock holdings, reflecting his belief in the company's potential, though these holdings experienced fluctuations over time, peaking in late 2020. His tenure was marked by notable insider trading activity, with transaction values reaching over $45 million in December 2020 alone. Dr. Pons has been recognized for his significant contributions to the biotech field and remains instrumental in the scientific direction of ALX, showing a blend of leadership and research expertise that guides the company forward.